RED: Treatment of human immunodeficiency virus-1 infection adults and
paediatric patients aged ≥2 years and weighing ≥14kg without present or past
evidence of viral resistance to the integrase inhibitor class, emtricitabine or
tenofovir. NHSE commissioned.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
